---

$2.41

+0.1050 ( +1.05% ) 27.6K

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2023-10-05	Sale	-42850.00	Ahlholm Frederick W
2023-10-05	Sale	-87050.00	Race Geoff
2023-10-05	Sale	-100450.00	Luthringer Remy
2023-09-29	Sale	-12500.00	Laghrissi-Thode Fouzia
2023-09-29	Sale	-12500.00	Kupfer David
2023-09-29	Sale	-12500.00	HILLEMAN JERYL L
2023-09-29	Sale	-12500.00	VAN HEEK G JAN
2023-09-29	Sale	-12500.00	HASLER HANS PETER

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.